iBio (NYSE American:IBIO) selected MUC16 as the target of its latest immuno-oncology program. MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and...
iBio (NYSEA:IBIO) received a patent from the U.S. Patent and Trademark Office issued a patent entitled, “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which covers a machine learning...
iBio (NYSEA:IBIO) will present two posters about its intelligence-powered RubrYc discovery engine at the Antibody Engineering and Therapeutics Conference in San Diego on Dec. 4-8. The conference features the latest...
iBio (NYSEA:IBIO) announced it is seeking to divest its contract development and manufacturing organization, iBio CDMO, in order to complete its transformation into an antibody discovery and development company...
iBio (NYSEA:IBIO) closed the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, marking an important step in iBio’s mission to bring more, and better, immunotherapies to the...
iBio (NYSEA:IBIO) provided an update on IBIO-202, its next-generation vaccine candidate under development for multi-variant COVID-19 disease. Unlike first-generation COVID vaccines that seek to provide immunity by...
iBio (NYSE American:IBIO) is presenting a poster on IBIO-101, its monoclonal antibody candidate for the treatment of solid tumors, at Frontiers in Cancer Immunotherapy 2022 in New York May 9-11. Preclinical evaluation...
iBio (NYSE American:IBIO) senior product manager, Rachel Jordan, Ph.D., will present a poster at the annual Protein & Antibody Engineering Summit conference in Boston this week titled, “Plant-Made Antibodies...
iBio (NYSE American:IBIO) updated progress on its lead COVID-19 vaccine program, IBIO-202, including a recently received the FDA response to its pre-IND package for IBIO-202. In light of the feedback received, the...
JMP Securities initiated coverage of iBio (NYSE American:IBIO) with a “market outperform” rating and price target of $1.50. The stock closed at 85 cents, up 19 cents, or 29%, on Nov. 29. iBio is a technology...